Navigation Links
Old drug holds promise against opportunistic lung bug
Date:8/19/2010

assistant professor in Pediatrics. "Since we reduced the response of the immune system, you would think the mice would get sicker. But instead, the mice treated with sulfasalazine were healthier. At first we thought it was due solely to the anti-inflammatory activity of the compound, but it turns out that sulfasalazine actually results in a reduced fungal burden. The drug helps the body clear the infection.

"We initially thought we had done something wrong, and so we repeated the experiment again and again. Then, when new technology was developed, we were able to document that the body cleared the infection more readily with sulfasalazine," added Wang.

Scientists have long known that the body's immune T cells are central to the body's response to fight off the infection. The Rochester team showed that the body's T cells spur macrophages to attack the fungus to engulf its particles and chew them up in a process known as phagocytosis.

While scientists have long suspected that role for macrophages, the Rochester team relied on a new technology to gather the first direct evidence of macrophages engulfing fungal particles. The scientists worked closely with Timothy Bushnell, Ph.D., and others at Rochester's Flow Cytometry Resources Core, investigating new ways to use lasers to capture images of molecular events. Bushnell's team ultimately connected the team with scientists at Amnis. Together the group developed a new way to capture macrophage phagocytosis in single cells from mice infected with Pneumocystis. The technology enabled the team to capture more than 40,000 such events, compared to just a handful when using conventional microscopy.

The team showed that as macrophage activity increased, the animals' health improved and levels of fungus decreased. For example, 17 days after infection, mice treated with sulfasalazine had nine times as many macrophages that had engulfed fungal particles compared to mice that had not been
'/>"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. AthletiCo Physical Therapy Holds July Cell Phone Drive
2. Chinese Biopharmaceutical Association Successfully Holds 15th Annual Conference
3. U.S. Panel Upholds Ban on Gay Men as Blood Donors
4. SISEL International Holds Successful Launch Events In Ukraine
5. Baden Elementary School holds VisionWalk to Fight Blindness
6. ShenoaDiamonds.com Holds Contest to Give Away $5,000 Diamond Ring, Spurred by Online Sales Growth
7. Construction Accident Lawyer Says Recent News Of Mine Disaster Holds Lessons For Construction Safety
8. ATSU –ASHS Holds Spring Commencement Ceremony
9. Morehead Associates, Inc. Holds Annual Peer to Peer Conference(TM)
10. Gene Holds Key to Embryonic Stem Cell Rejuvenation
11. Ongoing Toyota Recall Holds Serious Liability Implications For Manufacturer, but Consumers Must Be Protected, Says Texas Attorney Brad T. Wyly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with Dr. ... Paddock tackles topics including main men's health concerns, ... than men, and testosterone replacement therapy, among others. In ... on Doylestown Hospital’s website, Dr. Brad Paddock says, “A ... you notice pain, bulging, or asymmetry in your lower ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Praeclarus ... Made Simple as a valuable new resource for women ... two-thirds of American women work away from their children. ... touting the benefits of breastfeeding, but often feel unsupported ... nurse their babies. With its evidence-based insights, and written ...
(Date:7/12/2014)... Augusta, GA (PRWEB) July 12, 2014 ... Nova Medical Centers, is pleased to announce that it ... , This new facility will join four Atlanta-based ... will be located at 3209 Deans Bridge Road, and ... Monday through Friday. , “With Nova’s treatment philosophy ...
(Date:7/11/2014)... July 12, 2014 According to ... total market is expected to register a CAGR ... , Browse 71 market data tables and 76 ... on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market ...
(Date:7/11/2014)... 2014 (HealthDay News) -- People with the lowest incomes may ... artery disease (PAD), a new study suggests. People with ... the limbs, most often the legs. The condition causes leg ... arteries throughout the body. People with PAD have a higher ... from nearly 6,800 people with PAD who took part in ...
Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Poor More Prone to Leg Circulation Trouble 2
... the 1960s, surgeons experimented by transplanting chimpanzee organs into humans ... received a baboon heart and survived 20 days. // Since ... source for organs, tissues and cells to treat various diseases, ... the controversy surrounding cross-species transplant -- also known as xenotransplantation. ...
... diabetes is important because lifestyle changes and medication can prevent ... glucose tolerance test is used to identify high-risk individuals for ... study finds a cluster of risk //factors known as metabolic ... other risk factors. ,Metabolic syndrome has been shown ...
... osteoarthritis and rheumatoid arthritis cause joint pain and //stiffness ... no effective treatment to repair damaged cartilage. ... drug to prevent the onset of arthritis. The research ... a pivotal role in the onset of the condition. ...
... births of their first two children are more likely to deliver ... the same partner.// These babies are also ... results are the same even when researchers take into account the ... of birth. ,Researchers speculate that women who change ...
... the right mattress can make a difference. //Three-quarters of physicians ... a new study says they could be wrong. The new ... pain. ,Physicians often get frustrated when patients ask ... back pain. Few studies have been done on this issue ...
... night outlawed tobacco use in the Commonwealth's restaurants, taverns, ... on Sunday liquor-store sales as the House and Senate ... ,Working until nearly midnight, lawmakers also approved a sales ... thereby pumping up the state's flagging economy, and approved ...
Cached Medicine News:Health News:Animals Can give us a second chance at life 2Health News:Predictors for Type 2 Diabetes 2Health News:Changing Partners may put Expectant Mothers at Risk 2Health News:Senate assures ban on smoking 2Health News:Senate assures ban on smoking 3Health News:Senate assures ban on smoking 4
(Date:7/11/2014)... -- Research and Markets has announced the ... Film Industry Report 2014" report to their offering. ... Global And Chinese Medical X-Ray Film Industry Report 2014 ... state of the Global medical X-ray film industry with ... provides a basic overview of the industry including definitions, ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... Dec. 17 Novavax, Inc.,(Nasdaq: NVAX ) ... recombinant trivalent seasonal influenza virus-like particle (VLP),vaccine. The ... two,influenza vaccine programs that Novavax is developing using ... candidate is,currently in Phase I/IIa clinical trials., ...
... Product Developed Through Joint Venture Between Bristol-Myers Squibb and ... First of Its Kind in HIV Treatment -, ... The European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz ... ATRIPLA for commercialization in the,27 countries of the European ...
Cached Medicine Technology:Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
... world-class clinician documentation and electronic medical record ... the specific needs of intensive care units ... deep clinical functionality has secured its place ... in critical care, and its the most ...
... EncounterPRO Electronic Health Record ... System (WfMS) Specialties that ... and Immunology, Cardiology, Dermatology, ... Medicine, Neurology, Neurosurgery, Obstetrics ...
... developed a touchscreen EHR and is scheduled ... user can choose to use a mouse, ... eye contact while recording encounter results. If ... also runs on a pen tablet that ...
Dairylands Health Information Management solutions provides healthcare organizations a suite of integrated applications for managing patient records, optimizing reimbursement and regulatory complianc...
Medicine Products: